En-tête de navigationNavigation principaleSuiviFiche


Unité de recherche
INNOSUISSE
Numéro de projet
10278.1;9 PFDP-LS
Titre du projet
Synthetic Virus-Like Particles (SVLPs): A new Approach to Synthetic Vaccines and Nanomedicine
Titre du projet anglais
Synthetic Virus-Like Particles (SVLPs): A new Approach to Synthetic Vaccines and Nanomedicine

Textes relatifs à ce projet

 AllemandFrançaisItalienAnglais
Description succincte
Anzeigen
-
-
Anzeigen
Résumé des résultats (Abstract)
Anzeigen
-
-
Anzeigen

Textes saisis


CatégorieTexte
Description succincte
(Allemand)
Synthetic Virus-Like Particles (SVLPs): A new Approach to Synthetic Vaccines and Nanomedicine
Description succincte
(Anglais)
Synthetic Virus-Like Particles (SVLPs): A new Approach to Synthetic Vaccines and Nanomedicine
Résumé des résultats (Abstract)
(Allemand)
This Discovery grant should support the launch of the start-up (spin-out) company Virometix AG. The company will exploit a fundamentally new approach for the rational design and production of immuno-therapeutic drugs and vaccines using the tools of chemistry. The so-called SVLP technology provides a breakthrough in the creation of nanoscale biological assemblies for multivalent display of epitope mimetics. A new generation of synthetic vaccines will be developed using this technology to combat infectious and chronic human diseases. The technology is based on the use of virus-like particles made using artificial, fully synthetic building blocks, to deliver target antigens to cells in the immune system.
Résumé des résultats (Abstract)
(Anglais)
This Discovery grant should support the launch of the start-up (spin-out) company Virometix AG. The company will exploit a fundamentally new approach for the rational design and production of immuno-therapeutic drugs and vaccines using the tools of chemistry. The so-called SVLP technology provides a breakthrough in the creation of nanoscale biological assemblies for multivalent display of epitope mimetics. A new generation of synthetic vaccines will be developed using this technology to combat infectious and chronic human diseases. The technology is based on the use of virus-like particles made using artificial, fully synthetic building blocks, to deliver target antigens to cells in the immune system.